ACM
TEVA icon

Adalta Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

Adalta Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-32,800
Closed -$226K – 83
2019
Q3 		$226K Hold
32,800
– – 0.15% 73
2019
Q2 		$303K Hold
32,800
– – 0.2% 66
2019
Q1 		$514K Hold
32,800
– – 0.39% 51
2018
Q4 		$506K Hold
32,800
– – 0.47% 46
2018
Q3 		$707K Buy
+32,800
New +$761K 0.5% 47

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MVP
Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return

Adalta Capital Management's TEVA Position: Q4 2019 in Review

Adalta Capital Management sold out of Teva Pharmaceuticals (TEVA) in Q4 2019, closing a stake of 32,800 shares — an estimated $226K sold.

Adalta Capital Management first reported a position in TEVA in Q3 2018 and held it in 5 quarters. The position peaked at $707K in Q3 2018. 436 funds tracked by Wall St. Rank hold TEVA as of Q4 2019.

  • Adalta Capital Management reported no remaining Teva Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
  • Adalta Capital Management sold 32,800 Teva Pharmaceuticals shares in Q4 2019, an estimated $226K.
  • Adalta Capital Management first reported a position in Teva Pharmaceuticals in Q3 2018 and held it in 5 quarters.
  • Adalta Capital Management's Teva Pharmaceuticals position peaked at $707K in Q3 2018.
  • 436 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2019.

Based on Adalta Capital Management's 13F filing for Q4 2019, filed 14 Feb 2020.